Anti-oxidant therapy RTFit to treat alcoholic liver disease in India

Anti-oxidant therapy RTFit to treat alcoholic liver disease in India

Anti-oxidant therapy RTFit to treat alcoholic liver disease in India RTFit, an anti-oxidant nutritional supplement to treat liver diseases caused by alcoholism including cirrhosis is now available in India.

RTFit is a combination of two amino acids – taurine and racemethionine. The combination is found to be effective in treating liver disorders especially for alcoholic hepatitis.

Taurine, a sulphur-containing amino acid mostly found in free form in the tissues and bloodstream, has been identified as useful in treating people with alcohol dependency and is a detoxifying agent with antioxidant action that helps protect liver cells against various toxins.

The combination of taurine with racemethionine will have a synergistic actions, as both are hepatoprotective antioxidants, according to officials Zota Healthcare Ltd, which developed RTFit.

Racemethionine is an important sulphur containing amino acid with multiple functions throughout the body. Its role as an antioxidant and hepatoprotector has been widely documented. It protects hepatocytes and enhances their regeneration thus improving liver function.

Further, it acts as important sulphur and methyl group donor in detoxification reactions in liver cells. Both taurine and racemethionine are important for normal functioning of liver. During deficiency of taurine body converts methionine to taurine via cysteine.

The Surat-based Zota Healthcare Ltd, a pharma manufacturing, marketing and exports firm, is now planning to export RTFit to the overseas market.

Zota has already filed for patent with the Patent Cooperation Treaty (PCT), which will enable it to market the product in around 142 countries including several European, African and Middle East nations.

Zota is planning to market RTFit in 170 countries, soon after the PCT approval.

“We have received a good response in Indian market and recently applied with the PCT authority for patent. We expect to market RTFit in the major PCT member countries,” stated Ketan C Zota, managing director, Zota Healthcare.

Zota is expecting Rs 15 crore turnover for the product from India in the first year
and has set target to reach Rs 100 crore in five years. Further, it has also plans to enter the US market, where almost six per cent of the population suffers alcoholism related disease, he added.

Zota has already started the clinical trial of RTFit for various liver disorders with to evaluate the efficacy and safety of the product.

Zota announced earlier that it would initiate studies on the effect of the combination as a supplement for treatment of heart and skin disease in a later stage.